NPY1R and cancer: Using primary KPR172HC cancer cells, we tracked cancer cell movement on CDMs upon pharmacological NPY1R inhibition using the NPY1R antagonist BIBO3304 (Fig. 4, C to F) (87) to assess how inhibiting the NPY signaling axis might affect PC cell motility.